TRACON Pharmaceuticals (NASDAQ:TCON) Inc CEO Charles Theuer tells Proactive it has ended its fiscal year 2021 with cash and equivalents of $24.1 million as of December 31, 2021, as the company outlined some key milestones for the coming year. TRACON noted that it anticipates an interim ENVASARC safety and efficacy data review by the Independent Data Monitoring Committee (IDMC) in the second half of 2022. The company also said it plans to initiate dosing of a Phase 1/2 clinical trial of envafolimab with YH001 in the second half of 2022.
TRACON Pharmaceuticals ends FY2021 with $24.1M in the bank; reveals key milestones for 2022
